Lipedema is largely estrogen-mediated,[1] but progesterone shouldn’t be ignored in its role in vascular permeability and in balancing out estrogen. We don’t currently have much direct evidence on the effect of progesterone levels and lipedema, but there are theoretical considerations.
A 2025 narrative suggested that lipedema may have some kind of “progesterone-resistance,” sharing some mechanisms with gynecological disorders like endometriosis.[2] This is in part based on a 1995 study by O’Brien et al. who looked at progesterone receptors in human subcutaneous adipose tissue in a reproductive/endocrine context and showed progesterone receptors in this tissue, but this was not specifically lipedema tissue.[3] This distinction is important as is discussed in more detail by Lima et. al in their 2026 review which did not find any evidence to support the use of an endometriosis medication, gestrinone, in lipedema.[4]
However, there still may be connections with progesterone and lipedema. During a normal luteal phase, when progesterone levels are highest, many women experience symptoms like bloating and water retention. Anecdotally, many people with lipedema report cyclical symptom changes but no formal studies have tracked symptoms with the menstrual cycle. Studies not specific to lipedema do support this phenomenon, showing both plasma and interstitial colloid osmotic pressures are significantly reduced, with slight weight gain (~0.7 kg), which suggests increased water retention. Progesterone directly increases vascular permeability, [2] however in lipedema, things are more nuanced.
Luteal phase defect could create an estrogen-dominant state in relation to low progesterone. [3] Unopposed or relatively dominant estrogen action could theoretically worsen the underlying vascular and lymphatic dysfunction in lipedema through estrogen receptor-mediated pathways, even if the direct progesterone-mediated permeability effect is reduced.
On the other hand, certain estrogen-driven symptoms including swelling and pain could also be higher during peak estrogen (late follicular/ovulatory) timing. Due to the difficulty in hormone testing across the menstrual cycle, individual variation in both hormone balance and lipedema symptoms, determining the implications of menstrual hormone fluctuations on an individual’s lipedema is a clinical challenge.
In post-menopausal women, when progesterone levels are very low, oral micronized progesterone supplementation was associated with improved endothelial cell function.[4] Lipedema is characterized by endothelial cell dysfunction which worsens in menopause, but we currently don’t have data showing whether progesterone supplementation would be specifically beneficial for post-menopausal lipedema patients. Rabiee (2025) proposes that menopause represents a critical turning point driven by estrogen receptor imbalance and intracrine estrogen excess within adipose tissue, rather than by systemic estrogen levels. [5]
Overall, despite the evidence of hormonal drivers in lipedema, it remains a severely under-studied area for lipedema management. The 2026 Lüchinger systematic review, which specifically searched for associations between hormones and lipedema pathophysiology, identified no studies evaluating hormonal contraceptives, GnRH agonists, or any form of cycle suppression as lipedema interventions. [6] The 2023 Lipedema World Alliance Delphi consensus similarly does not include hormonal manipulation among its management recommendations. [7] The most comprehensive systematic review of lipedema therapeutics (Vazirnia et al., 2026) found evidence only for conservative therapies (compression, diet, aquatic exercise) and tumescent liposuction — no hormonal treatments were evaluated. [8]
Updated 8/11/2026
Sources
- Vazirnia A, Smart DR, Mohseni Y, Amron DM. Lipedema diagnosis, clinical manifestations, and therapeutics: a systematic review. Int J Dermatol. 2026;65(3):301-315.
- Lima MF. Gestrinone, lipedema, and the limits of theoretical extrapolation in clinical practice: a critical narrative review. J Vasc Bras. 2026;25:e20250240, DOI 10.1590/1677-5449.202502401
- Viana DPC, Câmara LC. Hormonal links between lipedema and gynecological disorders: therapeutic roles of gestrinone and drospirenone. J Adv Med Med Res. 2025;37(2):175-188. doi:10.9734/jammr/2025/v37i25731.
- O’Brien SN, Welter BH, Mantzke KA, Price TM. Identification of progesterone receptor in human subcutaneous adipose tissue. J Clin Endocrinol Metab. 1998;83(2):509-513. doi:10.1210/jcem.83.2.4561.
- Kruglikov IL, Joffin N, Scherer PE. The MMP14-caveolin axis and its potential relevance for lipoedema. Nat Rev Endocrinol. 2020;16(4):199-205.
- Goddard LM, Murphy TJ, Org T, et al. Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation. Cell. 2014;156(3):549-562.
- Practice Committees of the American Society for Reproductive Medicine and the Society for Reproductive Endocrinology and Infertility. Diagnosis and treatment of luteal phase deficiency: a committee opinion. Fertil Steril. 2021;115(6):1416-1423.
- Rezvani R, Gupta A, Smith J, et al. Cross-sectional associations of acylation stimulating protein (ASP) and adipose tissue gene expression with estradiol and progesterone in pre- and postmenopausal women. Clin Endocrinol (Oxf). 2014;81(5):736-745.
- Rabiee A. Lipedema and adipose tissue: current understanding, controversies, and future directions. Front Cell Dev Biol. 2025;13:1354321.
- Lüchinger JE, Pavicic E, Giachino CL, Stute P. Impact of hormones on lipedema development: a systematic literature review. Arch Gynecol Obstet. 2026;313(2):415-429.
- Kruppa P, Crescenzi R, Faerber G, et al. Lipedema World Alliance Delphi consensus-based position paper on the definition and management of lipedema: results from the 2023 Lipedema World Congress in Potsdam. Nat Commun. 2026;17(1):1482.
